Physician profile
Amy C Sim
NPI 1669670139
$1,823.84
in general payments reported to CMS, 2019-2025
16 companies · $20.44 in 2025
The $20.44 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $674 · 2022: $479 · 2024: $650 · 2025: $20.44.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $670.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $670.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $401.61 | 2021-2024 | |
| Amgen INC. | $288.96 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $176.95 | 2021-2025 | Dupixent |
| Janssen Biotech, INC. | $157.46 | 2022-2024 | Tremfya |
| Genzyme Corporation | $143.92 | 2022-2024 | |
| Sun Pharmaceutical Industries INC. | $106.86 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $95.01 | 2024 | Sotyktu |
| Pfizer INC. | $86.55 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $82.31 | 2021-2024 | |
| Lilly USA, LLC | $65.55 | 2022-2024 | Taltz |
| Ucb, INC. | $60.67 | 2024 | Bimzelx |
| Incyte Corporation | $56.47 | 2021-2022 | |
| Organogenesis INC. | $43.10 | 2021 | |
| Biofrontera INC. | $21.50 | 2022 | |
| Kyowa Kirin, INC. | $18.81 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $18.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Sim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.